Skip to main content

Table 3 Distribution of microbial isolates by total body surface area and by days after admission

From: Trends in microbial profile of burn patients following an event of dust explosion at a tertiary medical center

Isolated pathogens

Total

%

Total body surface area (%)

days after admission

< 39

40–49

50–59

60–69

70–79

80–89

> 90

1–3

4–7

8–14

15–30

>  31

Total sampling numbers of culture specimen

706

 

28

65

118

108

151

142

94

66

38

78

162

362

Total number of culture-positive sample

335

100

6

29

43

58

84

62

54

26

28

38

92

151

 Rate of culture-positive (%)

47.5

 

21.4

44.6

36.4

53.7

55.6

43.7

57.4

39.4

73.7

48.7

56.8

41.7

Total number of MDRO

104

 

1

9

17

21

20

19

17

2

6

9

35

52

 Rate of MDRO in total culture-positive (%)

31.0

 

0.96

8.7

16.3

20.2

19.2

18.3

16.3

1.9

5.8

8.7

33.7

50.0

Gram–positive cocci

97

29.0

4

11

16

18

21

11

17

7

3

12

26

49

Staphylococcus sp.

75

22.4

3

10

12

15

13

8

14

2

3

11

23

36

S. aureus

2

0.6

1

1

0

0

0

0

0

0

0

1

0

1

S. aureus (MRSA)

38

11.3

1

4

8

9

4

6

6

0

2

1

11

24

coagulase–negative staphylococcus

21

6.3

1

2

3

4

6

1

4

2

1

7

6

5

 other Staphylococcus sp.

14

4.2

0

3

1

2

3

1

4

0

0

2

6

6

Enterococcus sp.

9

2.7

1

1

2

3

2

0

1

4

0

1

0

4

E. faecium (VRE)

7

2.1

0

0

1

0

4

2

0

1

0

0

2

4

 Others

6

1.8

0

0

1

0

2

1

2

0

0

0

1

5

Gram–positive bacilli

4

1.2

0

0

3

0

1

0

0

2

2

0

0

0

Gram–negative bacilli

46

13.7

1

3

7

7

11

8

9

4

3

7

12

20

Enterobacteriaceae

Klebsiella pneumoniae

9

2.7

0

0

3

2

1

2

1

0

1

1

3

4

Klebsiella pneumonia (CRKP)

8

2.4

0

0

0

4

1

1

2

0

0

1

2

5

Escherichia coli

5

1.5

0

1

0

0

1

1

2

0

0

0

3

2

Enterobacter sp.

4

1.2

1

1

0

0

2

0

0

1

1

0

1

1

E. cloacae (CRE)

1

0.3

0

0

1

0

0

0

0

1

0

0

0

0

Proteus mirabilis

4

1.2

0

0

1

0

2

0

1

0

0

0

2

2

Serratia marcescens

3

0.9

0

0

1

0

1

0

1

2

0

0

1

0

Aeromonas hydrophila

2

0.6

0

1

0

0

1

0

0

0

1

1

0

0

 Others

10

3.0

0

0

1

1

2

4

2

0

0

4

0

6

Non-fermentative Gram-negative bacilli

132

39.4

0

10

17

22

32

27

24

10

14

13

44

51

Acinetobacter sp.

63

18.8

0

8

9

12

13

12

9

3

6

9

26

19

A. baumannii

1

0.3

0

0

0

1

0

0

0

0

1

0

0

0

A. baumannii (IRAB)

36

10.7

0

5

5

8

6

6

6

0

3

7

18

8

A. baumannii (PDRAB)

13

3.9

0

0

2

0

4

4

3

0

1

0

2

10

A. baumannii complex

13

3.9

0

3

2

3

3

2

0

3

1

2

6

1

Pseudomonas aeruginosa

33

9.9

0

0

3

5

10

6

9

2

3

0

10

18

P. aeruginosa (PDR-PA)

1

0.3

0

0

0

0

1

0

0

0

0

0

0

1

Stenotrophomonas maltophilia

13

3.9

0

1

2

1

3

3

3

2

2

1

4

4

Chryseobacterium indologenes

7

2.1

0

1

0

1

2

2

1

2

0

1

0

4

C. memingosepticum

5

1.5

0

0

0

1

2

1

1

1

2

1

1

0

Chryseobacterium spp.

4

1.2

0

0

0

1

1

2

0

0

0

0

0

4

Burkholderia cepacia

3

0.9

0

0

3

0

0

0

0

0

0

1

2

0

Pseudomonas putida

1

0.3

0

0

0

1

0

0

0

0

1

0

0

0

Moraxella osloensis

1

0.3

0

0

0

0

0

1

0

0

0

0

1

0

Moraxella morganii

1

0.3

0

0

0

0

0

0

1

0

0

0

0

1

Anaerobes

4

1.2

0

1

0

0

0

2

0

2

0

0

0

2

Fungus

51

15.2

1

4

0

11

19

13

4

1

6

6

10

28

Yeast

45

13.4

0

3

0

10

15

13

4

1

6

4

8

26

 Yeast

25

7.5

0

1

0

8

7

9

0

0

2

2

4

17

Candida spp.

14

4.2

0

2

0

2

5

2

3

1

3

2

4

4

 Others

6

1.8

0

0

0

0

3

2

1

0

1

0

0

5

MOLD

6

1.8

0

1

0

1

4

0

0

0

0

2

2

2

  1. MDRO multiple drug-resistant organisms, MRSA methicillin-resistant S. aureus, VRE vancomycin-resistant Enterococcus, CRKP carbapenem–resistant K. pneumonia, CRE, carbapenem-resistant Enterobacteriaceae, IRAB imipenem-resistant A. baumannii, PDRAB pandrug-resistant A. baumannii, PDR-PA pandrug-resistant P. aeruginosa
  2. *PDRAB was defined as being resistant to aminoglycosides, antipseudomonal carbapenems, antipseudomonal fluoroquinolones, antipseudomonal penicillins+β-lactamase inhibitors, extended-spectrum cephalosporins, folate pathway inhibitors, penicillins+β-lactamase inhibitors, polymyxins, tetracycline
  3. *PDRPA was defined as being resistant to aminoglycosides, antipseudomonal carbapenems, antipseudomonal cephalosporins, antipseudomonal fluoroquinolones, antipseudomonal penicillins+β-lactamase inhibitors, monobactams, phosphonic acids, polymyxins